Characterization of KIT mutation in melanoma
Authors:
- Yu-Hung WuYWYu-Hung Wu
- Chin-Yuan TzenCTChin-Yuan Tzen
- 1 March 2014
- journal article
- Published by Medknow in Dermatologica Sinica
- Vol. 32 (1) , 7-12
Abstract
Background/objectives: Recent studies have shown that the KIT mutational type appears to be a predictive marker for the efficacy of imatinib in treating melanoma. However, a wide range of KIT mutation rates was reported in different types of melanoma, suggesting that the mutation frequency of KIT may be associated with clinicopathological subsets of melanoma. Methods: To characterize their relationship, we sequenced exons 11, 13, 17, and 18 of KIT in 80 of 85 melanomas collected from two hospitals and categorized KIT mutation by tumor type, age and sex of patients, and mutation hot spots of KIT. Results: Our results showed that KIT mutation rates were 25%, 22%, and 8% in acral, mucosal, and cutaneous melanomas, respectively. Approximately 38% (5/13) of male patients with acral melanoma and 45% (5/11) of female patients with mucosal melanomas of the anorectal and genitourinary regions had a KIT mutation. Approximately 81% of KIT mutations occurred in L576P, K642E, V559A, and D820Y. Conclusion: This result shows that KIT mutation is enriched in a certain subset of melanoma patients and mutation hot spots do existKeywords
Funding Information
- Cathay General Hospital (CGH-MR-10126)
This publication has 29 references indexed in Scilit:
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or AmplificationJournal of Clinical Oncology, 2011
- V559A and N822I double KIT mutant melanoma with predictable response to imatinib?Pigment Cell & Melanoma Research, 2010
- Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KITBritish Journal of Cancer, 2010
- Phase II trial of imatinib mesylate in patients with metastatic melanomaBritish Journal of Cancer, 2008
- Dose‐dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutationPigment Cell & Melanoma Research, 2008
- Major Response to Imatinib Mesylate in KIT-Mutated MelanomaJournal of Clinical Oncology, 2008
- Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanomaCancer, 2006
- Lack of clinical efficacy of imatinib in metastatic melanomaBritish Journal of Cancer, 2005
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Prognostic Factors in Metastatic Melanoma: A Pooled Analysis of Eastern Cooperative Oncology Group TrialsJournal of Clinical Oncology, 2000